Nicolas Tilmans, Anagenex CEO
Seeking to 'close the loop' in drug discovery with machine learning, Catalio-backed biotech emerges from semi-stealth
Two years after securing seed funding and remaining in a state of “semi-stealth,” a San Francisco biotech keen on combining evolution and small molecule discovery …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.